**Materials and Methods** All patients treated with telaprevir or boceprevir since its inclusion in the hospital (January 2012) were included. We studied the medical records to see if patients were treatment-naive or a previously treated, and we checked the occurrence of adverse reactions associated with antiviral treatment. To calculate the adherence, dispensing records from the Pharmacy Service were used and percentage adherence was calculated. The primary end point was the rate of rapid virological response at week 4 for patients who completed one month of treatment and at week 12 for patients who completed three months. We used a formula for calculating percentage adherence, stating that a patient was adherent if treatment intake exceeded 95%.

**Results** At the time of the study (June 2012), 8 patients were treated with telaprevir (‘T group’) and 6 with boceprevir (‘B group’). In the T group there were 2 treatment-naive patients and 6 with no response to previous treatment. All patients who completed three months of treatment (4 patients) achieved rapid virological response. The other 4 patients completed one month of treatment and in all of them HCV RNA was undetectable at week 4. Pruritus and eczema were the most common adverse reactions in group T (in 90% of patients). In the B group, there were 3 treatment-naive patients and 3 previously treated. Four patients completed three months of triple treatment, but one of them did not reach rapid virological response. Regarding the 2 patients who completed one month of treatment, only one patient had undetectable HCV RNA at week 4. There were no adverse reactions related to boceprevir in this group. Patients of both groups were adherent to treatment.

**Conclusions** The addition of boceprevir or telaprevir to standard treatment increased the rates of rapid virological response, in treatment-naive and previously treated patients. The role of the Pharmacy Service is very important in promoting patient adherence despite the adverse effects that may occur.

No conflict of interest.

**Results** During the period studied, 15495 patients were hospitalised, 1044 received ceftriaxone, and 838 administrations of TPN were prepared for 85 patients. A total of 16 patients (18.8%), none of them neonates, were found to have received TPN and ceftriaxone at the same time: 10 staggered administrations, and 6 (7%) concomitantly; the patients were exposed to the described interaction. None of the 6 patients showed clinical complications arising from such an interaction.

As a result of this study, the TPN prescribing and validation programme in the pharmacy was updated. When calcium is prescribed in a TPN, the application automatically searches for ceftriaxone in the patient’s medicines and notifies the pharmacist in real time.

**Conclusions** Less than 10% of TPN patients could have suffered a ceftriaxone-calcium interaction in our hospital.

1. No neonates were exposed to this risk.
2. None of the patients had clinical complications due to this interaction.
3. The pharmacist TPN application was updated for real-time detection.

No conflict of interest.

**Background** A safety alert about the possibility of a potentially fatal interaction in patients, especially neonates, has been issued by the FDA. Patients treated with ceftriaxone and concomitant total parenteral nutrition (TPN) are at potential risk of pulmonary or intravascular precipitation of a ceftriaxone-calcium complex.

**Purpose** To assess patients with TPN at potential risk of suffering a calcium-ceftriaxone interaction, its clinical significance in our hospital, and to develop a software tool for real-time detection.

**Materials and Methods** Patient treatment (including ceftriaxone 1 g IV/IM and 2 g IV) from March 2010 to May 2011 was obtained using the Farmatools application of the Computerized-Physician-Order-Entry-System. TPN patient requirements, including neonates, were obtained from a database we had designed ourselves. Patients who required calcium-supplemented TPN and concomitant administration of ceftriaxone were selected. Finally, administrations or symptomatics or symptoms of intravascular or pulmonary precipitation were checked on patient Medical-Digital Health Records (Diraya).

To detect real-time ceftriaxone-calcium interactions when TPN is being prescribed, the Farmatools medicines database and the pharmacist TPN application were associated using ODBC (Open DataBase Connectivity).

**Reference**


No conflict of interest.

**GRP-182** THE CLINICAL PHARMACIST’S IMPACT ON THE APPROPRIATE USE OF MEDICINES IN ELDERLY PATIENTS

doi:10.1136/ejhpharm-2013-000276.182

1F Arnaud, 4Dubois, 1M Soulairaud, 1M Knight, 1C Roux, 1JM Kinowski. CHU Carêmeau, Pharmacy, Nîmes cedex 9, France; 4AFSSAPS, Hospital preparations, Paris, France

**Background** Adverse effects caused by the treatment are frequent in the elderly and most often result from an inappropriate prescription. Experts have published a list of potentially inappropriate medicines for the elderly (aged 75 and over) [1].

**Purpose** To measure the clinical pharmacist’s impact on compliance with this reference work.

**Materials and Methods** Our study was carried out in two units, the infectious and tropical diseases unit (SMIT) and a multipurpose medicine unit (MEPO) over a 1,5-month period. Drug prescriptions for patients aged 75 and over were analysed in the units after medicines reconciliation by the clinical pharmacist. Conformity with the list of potentially inappropriate medicines (MPIs) was assessed on the optimised medical record (BMO) and the hospital prescription entry. The list of MPIs was divided into three categories of treatment: unfavourable risk/benefit ratio (type 1), questional effectiveness (type 2) and unfavourable risk/benefit ratio and questionable effectiveness (type 3). When an inappropriate medicine was prescribed, the clinical pharmacist suggested interruption or alternative treatments.

**Results** Medicines reconciliation was conducted on 32 patients aged 75 and over in the two units (9 in SMIT and 23 in MEPO). Prescription of MPIs were identified for 11 patients (7 in MEPO and 4 in SMIT). The distribution of these MPIs was: 54.5% for type 1, 18.3% for type 2 and 27.2% for type 3. Medicines were stopped (54.5%), switched (18.2%) or continued (27.3%).

**Conclusions** We found more at-risk patients in MEPO than in the SMIT. In 27.3% of cases, treatments were continued after consulting the doctor and reassessing the risk/benefit ratio and effectiveness. In 72.7% of cases the clinical pharmacist’s contribution led to stopping or switching the MPI, confirming his essential role in the compliance with standards.